ORM PTO-1449	ATTY DOCKET NO.: 270.PFUS	SERIAL NO.: 10/540794
U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	APPLICANT: Dahi et al	
INFORMATION DISCLOSURE STATEMENT	FILING DATE: 3/20/2006	GROUP ART UNIT: 1616
BY APPLICANT 97 CFR 1,98(b))	EXAMINER NAME:	RECEIVED
Sheet 1 of 7		CENTRAL FAX CE

DEC 08 2006

		<u>U.S. F</u>	PATENT DOCUMENTS	
Examiner Crie initiats No	Document Number	Publication Date MM-DD-YYYY	Name of Papenties or Applicant of Cred Document	Pages, Columns, Lines, Where Resevant Passages or Relevant Figures Appear

		FOREIGN PA	ATENT DOCUMENTS		
Examiner Cite (httal No.	Foreign Palerx Document	Pubucation Date MR4-DD-YYYY	Name of Patentes of Applicant of Caed Document	Pages, Comms. Lines where Relevant Passages or Relevant Figures Appear	7

		NON PATENT LITERATURE DOCUMENTS	
Examoter of Mag	C _t te No	include name of the author (in CAPITAL LETTERS), tale of the anxiet (when appropriate), tale of the item (book, magazine, journal, senal, symposium, catalog, etc.), date, page(s), volumn-issue number(s), publisher, city and/or country where published	Τ
/A.P./		GILEAD SCIENCES, INC., ""Gilead Sciences to Acquire Triangle Pharmaceuticals for \$464 Million" Gilead to Launch Coviracil in 2003 Will Develop Co-Formulation of Viread and Coviracil", Press Release, 2002	

EXAMINER INICHTIYUH	EXAMINER	/Alton Pryor/
---------------------	----------	---------------

DATE CONSIDERED 05/14/2007

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449	ATTY DOCKET NO.: 270.PFUS	SERIAL NO.: 10/540,7	794
U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK BEFFECE			
INFORMATION DISCLOSURE STATEME	FILING DATE: 3/20/2006	GROUP ART UNIT:	161
BY APPLICANT 2 2 2007	EXAMINER NAME:		
Sheet 1 of 1			•

Examiner Cite Document Number Publication Date Name of Pate initials No. MM-DD-YYYY Applicant of Cited	U.S. PATENT DOCUMENTS				
Will-DD-11111 Applicant of Cited	ntee or Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			

			FOREIGN PA	ATENT DOCUMENTS		
Examiner initial	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	Т

	NON PATENT LITERATURE DOCUMENTS				
Examiner initial	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium,catalog, etc.), date, page(s), volumn-issue number(s), publisher, city and/or country where published.	T		
/A.P./		DE CLERCQ E., "Highlights in the Development of New Antiviral Agents", 2(2): 163-175, MINI REV MED CHEM, 2002			
/A.P.		DE CLERCQ E., "New Developmentss in anti-HIV chemotherapy", 56(1-2): 3-12, Farmaco, 2001			
7A.P.7		DE CLERCQ E., "New Development in Anti-HIV Chemotherapy", 8(13):1543-72, CURRENT MEDICINAL CHEMISTRY, 2001			
/A.P.		ISHIDA K, ASAO T., "Self-association and Unique DNA Binding Properties of the Anti-Cancer Agent TAS-103, a Dual Inhibitor of Topoisomerases I and II", 1587(2-3):155-163, BIOCHEM BIOPHYS ACTA, 2002			
/A.P.		LIU ET AL., "Thymidylate Synthase as a Translational Regulator of Cellular Gene Expression.", 1587(2-3):174-182, BIOCHEM BIOPHYS ACTA, 2002			

EXAMINER

/Alton Pryor/

DATE CONSIDERED 05/14/2007

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.